* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
Flutter Entertainment (FLTR.L) left the Main Market.
Market Movers:
Last Friday 31st, Amaroq (AMRQ.L), moved from AIM to the Main Market.
What’s baking in the oven?
It's a little empty
Banquet Buffet****
Altitude Group 26p £19.0m (ALT.L)
The technology and services provider specialising in end-to-end solutions for the branded merchandise and promotional products industry announced its results for the year ended 31 March 2026. Revenue increased by 19% to $44.4m driven by the full year contribution of the University Gear Shop contracts awarded in FY25 and growth in the Affiliate programme. The operating profit marginally improved to $3.8m and the Revenue mix is being actively re-shaped with investment refocused on growing high margin. A loss before tax of $0.2m was made compared to a profit of $0.4m for FY 25, after exceptional restructuring costs incurred during the year. Net debt was $0.1m against net cash $0.7m, reflecting the timing of the new contract and costs of the operational improvement programme. AIM iQ, an AI-enabled platform built specifically for the promotional products community, was launched and represents a significant milestone in the Group's technology roadmap. The CEO, states that with a clearer focus, a stronger platform and a disciplined operating model he is confident of the new strategy.
Crimson Tide 87.5p £5.8m (TIDE.L)
The provider of the mpro5 field service management software platform and service announced its audited results for the financial year ended 30 April 2026 (FY26). Revenues were £5.9m (FY25 16-month period: £8.0m) and a return to profitability, with profit before tax of £0.2m (FY25: loss of £2.3m). Annual recurring revenue (ARR) of £5.6m (FY25 16-month period: £7.2m) and cash and cash equivalents of £2.1m, up 64% (FY25: £1.3m), with no debt.
Croma Security Solutions Group 67.5p £9.3m (CSSG.L)
The innovation and service focused security solutions provider announced the completion of the acquisition of Added Security Technology Limited (AST), an established provider of intercom and door entry systems, locksmith services and hearing impaired living aids, based in Portsmouth. The total consideration for the acquisition is approximately £1.74m and includes cash balances of £0.80m and a freehold property, from which the business trades, valued at £0.53m. For the year ended 31 August 2025, AST generated revenue of £1.8m and adjusted EBITDA of £0.3m. The total consideration will be satisfied primarily in cash from the Group's existing cash reserves.
EDX Medical Group 10.75p £44.3m (EDX.L)
The developer of digital diagnostic products and services for major diseases, announced today that the Company and its partners have completed the development and technical validation of a pioneering rapid pneumonia test for critically ill patients that is now being deployed successfully in NHS clinical practice. The Ventilator-Acquired Pneumonia test, or 'VAP' test, enables rapid and informed changes to antibiotic prescribing and enhancement of clinical care in critically ill patients. The test, which helps guide treatment by detecting a broad range of viral, fungal and bacterial pathogens in a small sample of fluid drawn from the patient's lung, is now in service on The John Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge. Hospital acquired pneumonia cases alone cost the NHS an estimated £1.5bn per year and take almost one million bed days from service, much of which can be avoided by early detection.
eEnergy 2.95p £11.4m (EAAS.L)
The designers and installers of Solar PV, LED lighting, battery storage and EV chargers announced its unaudited half year results for the six months ended 30 June 2026 (H126). Revenue increased by 117% to £21.8m (H1-25: £10.1m) boosted by the delivery of the significant Mace project revenue across 62 school sites. Adjusted EBITDA pre-central / plc costs increased to £2.2m (H1-25: £1.4m) and net cash outflow from operating activities was £0.6m (H1-25: £5.3m inflow benefitted from the sale of the NatWest facility to Redaptive by £6.2m). Post the reduction in the pipeline of investment grade opportunities, on 22 June 2026 the Board reduced FY26 forecast revenue to £32.0m (FY25: £19.0m) and FY26 Adjusted EBITDA to £1.7m. The Company continues to trade in line with these expectations.
EnSilica 77p £99.8m (ENSI.L)
The fabless microchip maker with a growing portfolio of reusable IP, serving the Space and Communications, Industrial, and Automotive markets, announced that it has secured a second contract worth EUR1.7m from a European satellite manufacturer. The contract follows the completion of an earlier funded feasibility contract for a new satellite payload communications ASIC programme, which was one of the three satellite payload feasibility studies announced by the Company on 3 November 2025. This second contract represents the next phase of the original engagement, and is expected to be delivered over approximately 10 months.
First Development Resources 2.4p £3.3m (FDR.L)
The Australia-focused exploration company announced the completion of the first stage of the Phase I reverse circulation (RC) drilling programme, announced on 13 July 2026, at the Lander West Prospect within the wholly owned Selta Project in the Northern Territory, Australia. First stage of Phase I RC drilling programme completed with 1,593 metres drilled across eight holes and 243 rock-chip samples collected as part of an extensive geological mapping and reconnaissance programme. Drilling of the northern magnetic geophysics anomaly intersected mafic rocks and sulphide-bearing intervals, indicating a distinct geological setting. Assay results will be integrated with geological and geophysical datasets to refine the geological model and prioritise the next stage of exploration.
Genedrive 1.05p £16.9m (GDR.L)
The point of care pharmacogenetic testing company, notes the publication of the UK clinical guideline "MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity" in the British Journal of Clinical Pharmacology. The recommendations are intended to help prevent antibiotic-induced hearing loss (AIHL), which can occur following a single dose of an aminoglycoside antibiotic. Specifically in relation to point-of-care testing, the guidelines state that it should be considered where available in all acute clinical settings, naming the Genedrive MT-RNR1 ID Kit, which detects the m.1555A>G variant from a buccal swab and provides a result in approximately 26 minutes.
Hercules 43p £34.7m (HERC.L)
The UK power and infrastructure services group announced the launch of a dedicated Power & Energy Services division, supported by its own focused management team. This division will sit alongside Labour Supply Services and Construction Services as one of the Group's three core service divisions. Each division will be reported separately in the Company's financial results announcements, providing greater visibility of their individual performance and growth. This decision reflects the strong momentum Hercules is experiencing in one of the UK's most attractive long-term infrastructure markets and the Board's ambition to accelerate growth by expanding the Group's capabilities, customer relationships and operational capacity.
AQSE Market:
Sulnox Group 50p £75.8m (AQSE: SNOX)
The greentech company delivering lower fuel costs and emissions at zero capex announced its trading update for Q1 (1 April to 30 June 2026). Q1 revenues of £804.6k, representing growth of growth of 53.8% on Q1 2025 (£522.6k). Unaudited Q1 cash balance of £1,532.2k (Q4: £821.5k) after significant stock purchases for existing locations and a completed fundraising. Sulnox signed its largest commercial agreement to date: a new four-year supply agreement with EPS covering 1.2 million litres of Sulnox Eco, expanding fleet deployment from approximately 30 to more than 50 vessels. The CEO reports demand for technologies that deliver immediate reductions in fuel costs and emissions continues to grow and the company enters the second quarter with growing commercial momentum.
What’s baking in the oven?
Potential IPOs:***
Dual List:***
3rd August: Africa Bitcoin Corporation has announced its intention to dual list onto the AQSE Market. The company is a financial services group with a Bitcoin Treasury Strategy dedicated to providing financial services to SMEs across South Africa with a broad suite of solutions, including non-bank debt financing, novel equity linked instruments, insurance offerings and other tailored financial products.
The Company has a primary listing on the Main Board of the Johannesburg Stock Exchange and secondary listings on the A2X Proprietary Limited and the Namibia Securities Exchange and its ordinary shares also trade on OTCQB Market in the United States and the Frankfurt Stock Exchange. Expected admission date is 17th August.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
